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a b s t r a c t
To identify a classiﬁer in schizophrenia, blood gene expression proﬁling was applied to patients
with schizophrenia under different treatments and to controls. Expression of six genes discriminated
patients with sensitivity of 89.3% and speciﬁcity of 90%, supporting the use of peripheral blood as
biological material for diagnosis in schizophrenia.
& 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Schizophrenia is a neurodevelopment disorder, with genes and
chromosomal regions identiﬁed by linkage scans and genome-
wide association studies. A substantial body of evidence from
family, twin and adoption studies indicated that a genetic
component underlies increased risk for schizophrenia, although
replications of these results have been elusive (Tsuang et al.,
2001; Ng et al., 2009; Purcell et al., 2009; Shi et al., 2009;
Stefansson et al., 2009; Sun et al., 2010). These data support the
idea that schizophrenia involves many genes interacting with one
another and with environmental risk factors (Palha and Goodman,
2006; Ruano et al., 2008; Sun et al., 2010).
Currently, several studies assessing gene expression in
schizophrenia revealed important pathways, such as dopa-
mine signalling (Bonci and Hopf, 2005; Zhan et al., 2011). Most
were performed on post-mortem samples and consequently
include extraneous inﬂuences (e.g., post-mortem interval
brain tissue extraction, tissue pH and chronic exposure to
different antipsychotics). Although important ﬁndings were
associated with the disease pathophysiology, the impact on
establishing biological markers for clinical use has been
restricted.
Despite the limitations for data extrapolation, mRNA and
protein expression proﬁles from peripheral blood present
similar patterns to those found in brain tissue and may be
useful as a tool in diagnosis (Glatt et al., 2005; Sullivan et al.,
2006). Previous experiments identiﬁed over-expression of the
D3 dopamine receptor, BDNF, EGF and some chemokines as
blood markers in patients with schizophrenia (Ilani et al.,
2001; Domenici et al., 2010). These observations challenge the
research community to look for a molecular signature of
schizophrenia.
To identify a classiﬁer, we evaluated the peripheral blood
gene expression of a group of well-characterised patients with
schizophrenia compared with controls. Patients under three
different stable treatments were select to minimise gene
expression variations induced by a speciﬁc drug. The evalua-
tion employed a customised cDNA microarray platform
enriched for hormones and signalling pathways associated
with neurodevelopment.
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2. Materials and methods
2.1. Casuistic
Patients were recruited at the schizophrenia outpatient pro-
gramme of Hospital de Clı´nicas de Porto Alegre, Porto Alegre (RS)
with universal access. Selection and exclusion criteria are
described in the supplemental material (Supplemental data 1).
Patients under clozapine (CLO, n¼10), risperidone (RIS, n¼10)
and haloperidol (HAL, n¼8) treatments and 10 controls (CON)
were selected. Controls and patients had a mean age of 25.3 years
and 33.4 years, respectively. Although there is a statistical
signiﬁcance concerning age (Po0.05), given by one-way analysis
of variance (ANOVA), between both groups, this is not biologically
relevant (Colantuoni et al., 2011).
Patients with schizophrenia displayed similar ages, ages of
illness onset and lengths of illness. Given by Brief Psychiatry
Rating Scale, tested by the Kruskal–Wallis test, at the time of
blood collection, patients under HAL treatment exhibited higher
levels of symptoms than patients under CLO or RIS treatments
(P¼0.04). The clinical features of all samples are depicted in
Supplemental Table 1.
The study protocol was approved by the ethics committee of
the hospital and was performed in accordance with the Declara-
tion of Helsinki. All subjects were advised about the procedure
and signed (in conjunction with a relative, if patients) a written
informed consent.
2.2. cDNA microarray experiments
Total RNA extraction and ampliﬁcation besides microarray
experiments are detailed in the supplemental material (Supple-
mental data 2), performed as described (Mello et al., 2009;
Maschietto et al., 2011). Microarray data were deposited with
the Gene Expression Omnibus (GEO) under accession number
GSE19112.
2.3. Statistical analysis
For the cDNA microarray experiments, signiﬁcance analysis of
microarray (SAM) (Tusher et al., 2001) with 1000 permutations
and false discovery ratio (FDR) of 0.2 by MEV (MultiExperiment
Viewer) software (Saeed et al., 2003) were used to identify
differentially expressed genes.
Genes were functionally classiﬁed according to biological
processes through Gene Ontology (GO), using FunNet (Prifti
et al., 2008). To ﬁnd hyper-represented chromosome regions,
hypergeometric test with multiple test adjustments was applied
using WebGestalt (Zhang et al., 2005). Both comparisons consid-
ered only genes spotted in the microarray platform.
Using the microarray data we applied Pearson correlation
between pairs of differentially expressed genes across all subjects
in every group. This approach quantiﬁes the transcriptomic
interactions represented by Pearson correlation coefﬁcients
(PCCs). A delta between absolute PCC values from CLO, RIS, HAL
and CON was performed (Fukuoka et al., 2004). To ensure
exclusive differences, we set a threshold of a delta higher than
0.5 between CON and the three schizophrenic groups. Networks
were constructed using Cytoscape (Cline et al., 2007).
Stepwise linear discriminant functions identiﬁed genes able to
discriminate patients with schizophrenia from controls. The
classiﬁcation of a given subject was determined by its nearness
to the centroids of the various groups in terms of the Mahalanobis
generalised distance (De Leona and Carriere, 2005). The perfor-
mance of linear discriminant functions was evaluated using
leave-one-out cross-validation, in which each case is classiﬁed
by the discriminant functions derived from all other cases.
3. Results
3.1. Characterisation of differentially expressed genes among
subjects
Comparisons among all groups of patients with schizophrenia
and controls identiﬁed 32 differentially expressed genes. Annota-
tion of these genes using the GO database identiﬁed molecular
functions and biological processes with which these genes are
involved (Supplemental Table 2). To identify preferentially repre-
sented chromosome regions, the location of 32 differentially
expressed genes were compared with all genes in the microarray
platform and showed hyper-representation of the cytobands 5q35
(P¼0.0187) and 16p (P¼0.0068), named 16p11.2, 16p12.1 and
16p13.3.
3.2. Identiﬁcation of altered expression in gene pairs in the
schizophrenic groups
To identify gene pairs with altered co-expression in the
schizophrenic group, co-expression of each gene pair among the
32 differentially expressed genes in the three schizophrenic
groups (CLO, RIS and HAL) was compared with that of the gene
pairs in CON revealing 16 gene pairs consisting of 17 genes with
PCC Z0.5 (Supplemental Figure 1, Supplemental Table 3) in the
patients with schizophrenia, independent of drug use.
HERPUD1 presented the highest number of alterations of co-
expression with 10 genes (BTAF1, EIF1, GNB2L1, HOXA13, ITM2B,
KRT17, PEG3, PRICKLE2, RPS2 and RPS4X), followed by SEPHS2
(three genes), FUS, RPS8, HOXA13, GNB2L1 and KRT17 (two genes).
Interestingly, a great number of genes that altered co-expression
are located at chromosome 16p (Supplemental Table 2).
This analysis also provided 84, 31 and 81 gene pairs as exclu-
sively altered in CLOxCON, RISxCON and HALxCON, respectively,
suggesting drug-speciﬁc alterations (Supplemental Tables 4–6).
3.3. A classiﬁer based on gene expression from peripheral blood is
able to discriminate patients with schizophrenia from controls
To determine whether the use of gene expression from blood
samples could be used as a diagnostic tool to molecularly
distinguish patients with schizophrenia from controls, indepen-
dent of treatment, expression values of the 32 genes were used to
construct a linear discriminant function. All patients with schizo-
phrenia and controls were correctly classiﬁed, although the leave-
one-out procedure demonstrated that using the 32 genes resulted
in an over-ﬁtting model that could not be generalised (Table 1A,
Supplemental Fig. 2A).
Consequently, a data reduction method, performed by a step-
wise selection of linear combinations of six out of the 32 genes
and classiﬁed by an individual Mahalanobis generalised distance,
was applied to the 32 genes to construct discriminant functions
and also tested using the leave-one-out procedure. Combined
expressions of HERPUD1, HOXA13, CTNNA1, SULT1A1, PIK3R3 and
MALAT1 were able to discriminate patients with schizophrenia
from controls in the same group of samples. In the independent
classiﬁcation, 25 out of 28 patients with schizophrenia were
correctly classiﬁed, resulting in a sensitivity of 89.3% and a
speciﬁcity of 90% (Table 1B, Supplemental Fig. 2B).
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4. Discussion
This study identiﬁed a gene signature in blood samples that
was capable of discriminating male patients with schizophrenia
under different treatments from mentally healthy individuals.
Although it is important to stress that a larger and independent
group, which includes women with schizophrenia, must be
tested, we have chosen the male gender due to the possible
confounding of female hormonal states at the time of blood
sampling and the effect of contraceptives, which inﬂuence on
the gene expression proﬁles (Nakamura et al., 2008). Besides, we
used a customised microarray platform, with enrichment for
neurodevelopment genes, due to their involvement with the
disease (Palha and Goodman, 2006; Ruano et al., 2008) and the
current accepted view that schizophrenia is a neurodevelopment
disorder in which genes and environment interplay for disease
onset and progression.
Although the differentially expressed genes identiﬁed in this
study were not previously directly associated with schizophrenia,
they either participate in biological processes or have their
localisation already described as being involved with the disease.
Of note, we found that individuals with schizophrenia display
altered expression of genes involved in functional processes
already described in schizophrenia such as neuronal differentia-
tion, metabolic processes and cell cycle (Martins-de-Souza et al.,
2009, 2010; Paulsen et al., 2011; Fan et al., 2012).
Differential gene expression measures were also used to
construct co-expression networks. By interacting with each other,
genes and their products form complex cellular networks, whose
perturbations can result in altered phenotypes (Vidal et al., 2011).
We provided gene pairs for which their co-expression directions
in patients with schizophrenia (CLO, RIS and HAL) and healthy
individuals (CON) were opposite. In a co-expression network, the
combination among the genes does not mean, necessarily, a
physical or biochemical interaction; however, disruption on
gene–gene co-expression can result in alterations based on
functional roles of these genes. For example, HERPUD1 presented
the highest number of alterations of co-expression. This gene
encodes a stress-response protein localised in the endoplasmic
reticulum (ER) membrane of neurons and other cell types, and ER
stress has been associated with aberrant protein degradation in
the pathogenesis of neurodegenerative disorders (Slodzinski et al.,
2009). These ﬁndings may open up new avenues for the identi-
ﬁcation of novel blood markers and/or new drug targets for
schizophrenia.
Disease classiﬁcation has already been performed as an
important approach in the molecular diagnosis and classiﬁcation
of several illnesses, including schizophrenia (Tsuang et al., 2005;
Bowden et al., 2006; Kuzman et al., 2009; Woelk et al., 2011). We
suggest that peripheral blood mRNA proﬁling is a feasible way to
discriminate patients from controls, regardless of antipsychotic
treatment. The combined expression of six genes (HERPUD1,
HOXA13, CTNNA1, SULT1A1, PIK3R3 and MALAT1) was able to
identify 89.3% and 70% of patients with schizophrenia and
controls, respectively. These data suggest that these genes might
be important for the disease, as only three patients with schizo-
phrenia were misclassiﬁed (one and two under HAL and CLO
treatments, respectively). It is very important to have validation
of these results in a larger and independent sample.
Altogether, in spite of the relatively small number of samples
evaluated, this study suggested that peripheral blood may be
useful for diagnosis of schizophrenia. Also, a set of six genes was
able to discriminate patients with schizophrenia from controls,
implying an expression signature for the disease that must be
tested by future studies whether these genes are able to classify
ﬁrst episode and un-medicated patients.
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